Danaher Corporation $DHR Shares Sold by Milestones Administradora de Recursos Ltda.

Milestones Administradora de Recursos Ltda. trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 36.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 87,608 shares of the conglomerate’s stock after selling 50,181 shares during the quarter. Danaher comprises about 3.5% of Milestones Administradora de Recursos Ltda.’s holdings, making the stock its 10th biggest holding. Milestones Administradora de Recursos Ltda.’s holdings in Danaher were worth $19,410,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Canoe Financial LP raised its holdings in Danaher by 43.3% in the 3rd quarter. Canoe Financial LP now owns 800,124 shares of the conglomerate’s stock worth $169,434,000 after acquiring an additional 241,910 shares during the last quarter. Strengthening Families & Communities LLC lifted its position in Danaher by 3.4% in the 3rd quarter. Strengthening Families & Communities LLC now owns 3,638 shares of the conglomerate’s stock valued at $806,000 after acquiring an additional 121 shares in the last quarter. Atticus Wealth Management LLC purchased a new stake in Danaher during the 3rd quarter valued at $221,000. Quadrant Capital Group LLC boosted its stake in Danaher by 14.1% during the 3rd quarter. Quadrant Capital Group LLC now owns 14,583 shares of the conglomerate’s stock valued at $3,250,000 after purchasing an additional 1,798 shares during the last quarter. Finally, Bell Bank increased its holdings in shares of Danaher by 8.5% in the 3rd quarter. Bell Bank now owns 1,461 shares of the conglomerate’s stock worth $324,000 after purchasing an additional 114 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

NYSE DHR opened at $233.99 on Thursday. The stock has a market capitalization of $164.49 billion, a price-to-earnings ratio of 41.56, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The business’s fifty day moving average price is $215.25 and its 200-day moving average price is $196.84.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, topping the consensus estimate of $1.92 by $0.19. The firm had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.89 EPS. On average, equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Adjusted EPS beat expectations: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus and up from $1.89 a year earlier. Profitability was supported by strength in the Biotechnology segment. Danaher Reports Third Quarter 2026 Results
• Positive Sentiment: Full-year outlook raised: Management increased its 2026 adjusted EPS guidance to $8.57-$8.62, above the prior outlook and analyst expectations. The improved forecast signals confidence that customer demand and operating trends are continuing to recover. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Biotechnology momentum improved: Biotechnology orders grew at a mid-teens rate in the quarter, while management described improving trends across end markets. Danaher also said it has the technological “building blocks” to pursue future growth from artificial intelligence in drug discovery. Danaher says it has building blocks for AI drug discovery growth
• Neutral Sentiment: Revenue was broadly on target: Third-quarter revenue rose 8.3% year over year to $6.55 billion, just below the $6.56 billion consensus. The near miss was outweighed by the earnings and guidance beats but limits the evidence of a broad-based sales acceleration. Danaher’s Q3 2026 Earnings Results
• Negative Sentiment: Mixed segment performance and leadership uncertainty remain risks: The Masimo acquisition helped offset declines in respiratory diagnostic sales, while investors continue to assess the implications of Danaher’s CEO transition. These issues could restrain the stock if weaker businesses do not stabilize. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales

Analyst Ratings Changes

Several equities research analysts recently commented on DHR shares. The Goldman Sachs Group lifted their price objective on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Royal Bank Of Canada upped their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Morgan Stanley raised their price target on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Barclays raised their price target on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Finally, Evercore reiterated an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.